Rekha Chandran, MD
Hematology & Oncology · Seattle, WANPI 1457393878
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $676 of the $973 with a category attached, or 69.4%. 10 manufacturers reported payments, led by Seagen Inc. at 31.4% of the total. Reporting peaked in 2024 at $392 and has fallen 85.1% since, to $59 in 2025. That places this record below the midpoint for hematology & oncology clinicians in WA, where the typical reported total is $899.
Across 16 payments — averaging $60.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$305
- Johnson & Johnson$273
- AbbVie$154
- Novo Nordisk$77
- Intuitive Surgical$52
- Incyte Corporation$49
- plus $63 from 4 others
Across 5 payments — averaging $68.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$342
What the payments were for
- Food & beverage$67669%
- Education$29731%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 3 | $305 |
| Johnson & Johnson(2 entities) | 3 | $273 |
| AbbVie | 3 | $154 |
| Novo Nordisk | 1 | $77 |
| Intuitive Surgical | 1 | $52 |
| Incyte Corporation | 1 | $49 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Clovis Oncology, Inc. | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $13 |
| Gilead | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$973 in reported general payments places this provider in the 50th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| InlytaAxitinib | 12 | $233,883 |
| Exemestane | 49 | $4,073 |
| Prochlorperazine Maleate | 64 | $606 |
| Dexamethasone | 83 | $487 |
| Potassium Chloride | 48 | $445 |
| Anastrozole | 23 | $400 |
| Ondansetron Hcl | 42 | $353 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 20 | $300 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 15 | $256 |
| Letrozole | 13 | $224 |
| Acyclovir | 25 | $214 |
| Allopurinol | 20 | $121 |
| Olanzapine | 52 | $117 |
| Pantoprazole Sodium | 16 | $93 |
| Levofloxacin | 15 | $92 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Seattle
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
- Celestia HiganoSeattle$164K
- Ryan CassadaySeattle$151K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.